HHS funds vaccine candidates for Marburg, Sudan ebolavirus
The Department of Health and Human Services yesterday awarded $20.5 million to develop vaccine candidates for Marburg virus and Sudan ebolavirus, which are in the same family of viruses as the Ebola virus outbreak in the Democratic Republic of the Congo. The last outbreaks of Marburg virus and Sudan ebolavirus were in Uganda, in 2017 and 2012, respectively. The Sabin Vaccine Institute will conduct nonclinical studies and complete manufacturing activities to advance the development of the vaccine candidates under a contract with HHS’s Biomedical Advanced Research and Development Authority. BARDA also is helping to develop and procure vaccines, therapeutics and diagnostics for the Ebola strain circulating in the Congo.
Related News Articles
Headline
There are now 17,180 confirmed cases of cyclosporiasis in the U.S., the Centers for Disease Control and Prevention reported Aug. 25. At least 11,844 additional…
Headline
In this conversation, Kardie Tobb, D.O., a non-invasive preventative cardiologist at Cone Health, explains how multidisciplinary teams are breaking down…
Headline
There have been 15,716 confirmed cases of cyclosporiasis across 47 states, Washington, D.C., and Puerto Rico since May 1, the Centers for Disease Control and…
Headline
The Common Health Coalition announced Aug. 13 that it will receive $100 million in funding from the OpenAI Foundation for a new initiative using artificial…
Headline
The Centers for Disease Control and Prevention Aug. 11 released a health advisory on the risk of severe arboviral disease among patients receiving B-cell-…
Headline
The Centers for Disease Control and Prevention yesterday announced that the ongoing cyclosporiasis outbreak linked to iceberg lettuce has expanded to 15 states…